Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Plasma cell 1Lymphoid 1Dermatologic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Non-Hodgkin 31Lymphoma 20Lymphoma, Mantle-Cell 18Multiple Myeloma 17Lymphoma, Follicular 16Lymphoma, Large B-Cell, Diffuse 14Hodgkin Disease 11Lymphoma, B-Cell, Marginal Zone 9Recurrence 6Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Lymphoma, B-Cell 3Leukemia, Lymphoid 3Hematologic Diseases 3Burkitt Lymphoma 3Small Cell Lung Carcinoma 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Hairy Cell 2

Interventions

Peripheral Blood Stem Cell Transplantation 12Rituximab 9Tacrolimus 8Mycophenolic Acid 8fludarabine phosphate 7Cyclophosphamide 7Whole-Body Irradiation 6Cyclosporine 5Radiotherapy 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Busulfan 4Antilymphocyte Serum 4immunotoxin HA22 3fludarabine 3Etoposide 3Dexamethasone 3Calcium Dobesilate 3plerixafor 2merphos 2Therapeutics 2Sirolimus 2Ondansetron 2Melphalan 2Ipilimumab 2Flow Cytometry 2Diphenhydramine 2Darbepoetin alfa 2Cord Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Leukemia, Hairy Cell × Bendamustine Hydrochloride × Clear all
NCT01059786 2025-06-12

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
69 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Hairy Cell, Neoplasm, Residual

NCT01326702 2019-12-16

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Completed
43 enrolled 18 charts
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡